The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.
The investigational live intranasal vaccine was safe and well-tolerated when given concomitantly with Fluzone HD and the combination outperformed the latter given by itself.
Individuals 6 months and older should receive updated COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season, the agency recommended.